Dow Debate: Can Merck & Co., Inc. Chase Johnson & Johnson In 2014?

After a strong start to the year, can Merck (NYSE: MRK) beat Johnson & Johnson (NYSE: JNJ) in 2014?

Feb 18, 2014 at 7:56PM

^SPX Chart

^SPX data by YCharts

Last year saw shares in Merck (NYSE:MRK) unable to keep pace with sector peer Johnson & Johnson (NYSE:JNJ), as the latter posted total returns of 33.2%, while the former was only able to deliver a total return of 25.6%. The total returns of the two main indices, meanwhile, were 26.4% (S&P 500) and 24.2% (Dow).

Indeed, 2014 has seen the trend of 2013 turned upside down, with Merck significantly outperforming Johnson & Johnson in the first six weeks of the year. Merck is currently up 11.6%, while Johnson & Johnson has fared only slightly better than the S&P 500 (Johnson & Johnson is up 0.9%, while the S&P 500 is down 0.4%), with the Dow being down 2.5%. Can Merck continue to outperform through 2014, or will its chase of Johnson & Johnson end in failure?

Fourth-quarter results
The fascinating aspect of the share price performance of Merck and Johnson & Johnson in 2014 has been that Merck has delivered disappointing fourth quarter results, while Johnson & Johnson's results were far better.

For instance, Merck's net profit fell by 14% in the fourth quarter, while Johnson & Johnson's bottom line grew by 5.5% when compared with the fourth quarter of 2012. However, it is the former and not the latter whose share price has significantly outperformed the market in 2014.

Of course, the disappointing figures from Merck were widely expected, and it is likely that they were priced in, explaining (to some degree) the relatively poor share price performance in 2013. The main reason for the decline in profits is generic competition, with Merck suffering from patent expiry and the subsequent loss of profit as margins are competed away.

However, this challenge is one Merck faces exclusively. Jonson & Johnson is also facing challenges of its own with regard to generic competition but, unlike Merck, Pharmaceuticals account for around 40% of its revenue, with Medical Diagnostics and Consumer Goods making up the remaining 60% (split 40/20). This means that Johnson & Johnson's profit is better-shielded from patent expiries and, as such, its profits are likely to be more resilient, if less spectacular, in the long run.

Pipeline progress
Still, both companies are pushing hard to overcome their patent woes. Merck, for instance, continues to experience positive updates from its pipeline of drugs, with lambrolizumab being designated a Breakthrough Therapy for patients with advanced melanoma, for instance.

Meanwhile, Johnson & Johnson has had success with FDA approvals for ibrutinib (lymphoma) and simeprevir (hepatitis C), while canagliflozin (type 2 diabetes) was approved in Europe. The company is also seeking to grow its non-Pharmaceuticals capability and has raised capital already in 2014 through the sale of its blood testing unit to Carlyle Group for just over $4 billion.

Both companies easily beat the S&P 500 yield of 1.96%, with Johnson & Johnson yielding 2.5% and Merck yielding 3.1% (all TTM). Both companies are being relatively conservative with regards to the proportion of earnings paid out as dividends, with Johnson & Johnson paying out 42% of profit as a dividend, while Merck paid out 49% in 2013.

This highlights the conservative stance adopted by both companies, since earnings per share (EPS) are forecast to grow by just 7.5% for Merck in the next two years (although this could be due to a share buyback, as net profit for the company is set to fall). Meanwhile, Johnson & Johnson is forecast to deliver EPS growth of 13.7% over the next two years and is set to grow dividends per share by 24% over that period. While this would increase the payout ratio, it would still be just 45% in 2015, which seems conservative for a well-diversified, major health care stock.

On a relative basis ...
Interestingly, sector peer, Bristol-Myers Squibb (NYSE:BMY), pays out around 77% of net profits as dividends. It yields 2.6% and, despite a forecast for EPS to fall by 7% in the next two years, dividends per share are expected to be increased by 5.2% over the same time period. This highlights the difference in policies of the three companies, with Bristol-Myers Squibb choosing to divest assets (such as the diabetes alliance with AstraZeneca) to reinvest in the business, rather than reduce the payments it makes to shareholders.

Looking ahead
Although it had a challenging fourth quarter of 2014, Merck looks well placed to chase Johnson & Johnson in 2014. Sure, it needs to generate positive news flow from its pipeline, as this is the key to its future performance. However, its pipeline is encouraging and has the potential to turn the business around. Johnson & Johnson remains a relatively stable stock and should have a strong 2014, with both stocks having the potential to beat the S&P 500 and the Dow this year.

9 rock-solid dividend stocks
One of the dirty secrets that few finance professionals will openly admit is that dividend stocks as a group handily outperform their non-dividend-paying brethren. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers